help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Molecular Endocrinology, doi:10.1210/me.2004-0434
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Masuyama, H.
Right arrow Articles by Hiramatsu, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Masuyama, H.
Right arrow Articles by Hiramatsu, Y.
Molecular Endocrinology 19 (5): 1170-1180
Copyright © 2005 by The Endocrine Society

The Pregnane X Receptor Regulates Gene Expression in a Ligand- and Promoter- Selective Fashion

Hisashi Masuyama, Naoko Suwaki, Yoko Tateishi, Hideki Nakatsukasa, Tomonori Segawa and Yuji Hiramatsu

Department of Obstetrics and Gynecology, Okayama University Medical School, Okayama 700-8558, Japan

Address all correspondence and requests for reprints to: Hisashi Masuyama, M.D., Ph.D., 2-5-1, Shikata, Okayama 700-8558, Japan. E-mail: masuyama{at}cc.okayama-u.ac.jp.

Recent studies have revealed that pregnane X receptor (PXR) can function as a master regulator to control the expression of phase I and phase II drug-metabolizing enzymes, as well as members of the drug transporter family, including multiple drug resistance (MDR) 1, which has a major role in multidrug resistance. Previously, we have demonstrated that steroid/xenobiotics metabolism by tumor tissue through the PXR-cytochrome P-450 3A (CYP3A) pathway might play an important role in endometrial cancer. In this study, we examined which endocrine-disrupting chemicals (EDCs) and anticancer agents might be ligands for PXR and whether these chemicals enhanced PXR-mediated transcription through two different PXR-responsive elements (PXREs), CYP3A4 and MDR1, in endometrial cancer cell lines. Some steroids/EDCs strongly activated PXR-mediated transcription through the CYP3A4-responsive element compared with the MDR1-responsive element, whereas these steroids/EDCs also enhanced the CYP3A4 expression compared with the MDR1 expression. In contrast, the anticancer agents, cisplatin and paclitaxel, strongly activated PXR-mediated transcription through the MDR1-responsive element compared with the CYP3A4-responsive element, whereas these drugs also enhanced the MDR1 expression compared with the CYP3A4 expression. We also analyzed how these ligands regulated PXR-mediated transcription through two different PXREs. In the presence of PXR ligands, there was no difference in the DNA binding affinity of the PXR/retinoid X recptor heterodimer to each PXRE, but there were different interactions of the coactivator to each PXR/PXRE complex. These data suggested that PXR ligands enhanced PXR-mediated transcription in a ligand- and promoter-dependent fashion, which in turn differentially regulated the expression of individual PXR targets, especially CYP3A4 and MDR1.

NURSA Molecule Pages Link:

Nuclear Receptors:   TRα  |  PXR  |  CAR  |  RXRα
Coregulators:   TRAP220  |  SRC-1  |  AIB1
Ligands:   17β-Estradiol



This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
D. Gupta, M. Venkatesh, H. Wang, S. Kim, M. Sinz, G. L. Goldberg, K. Whitney, C. Longley, and S. Mani
Expanding the Roles for Pregnane X Receptor in Cancer: Proliferation and Drug Resistance in Ovarian Cancer
Clin. Cancer Res., September 1, 2008; 14(17): 5332 - 5340.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
F. Pettersson, N. Hanna, M. Lagodich, D. Dupere-Richer, M.-C. Couture, C. Choi, and W. H. Miller Jr.
Rexinoids Modulate Steroid and Xenobiotic Receptor Activity by Increasing Its Protein Turnover in a Calpain-dependent Manner
J. Biol. Chem., August 8, 2008; 283(32): 21945 - 21952.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Goel, M. Cohen, S. N. Comezoglu, L. Perrin, F. Andre, D. Jayabalan, L. Iacono, A. Comprelli, V. T. Ly, D. Zhang, et al.
The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development
Clin. Cancer Res., May 1, 2008; 14(9): 2701 - 2709.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
H. Wang, H. Li, L. B. Moore, M. D. L. Johnson, J. M. Maglich, B. Goodwin, O. R. R. Ittoop, B. Wisely, K. Creech, D. J. Parks, et al.
The Phytoestrogen Coumestrol Is a Naturally Occurring Antagonist of the Human Pregnane X Receptor
Mol. Endocrinol., April 1, 2008; 22(4): 838 - 857.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y. Chen, Y. Tang, M.-T. Wang, S. Zeng, and D. Nie
Human Pregnane X Receptor and Resistance to Chemotherapy in Prostate Cancer
Cancer Res., November 1, 2007; 67(21): 10361 - 10367.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
H. Masuyama, H. Nakatsukasa, N. Takamoto, and Y. Hiramatsu
Down-Regulation of Pregnane X Receptor Contributes to Cell Growth Inhibition and Apoptosis by Anticancer Agents in Endometrial Cancer Cells
Mol. Pharmacol., October 1, 2007; 72(4): 1045 - 1053.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
L. Cerveny, L. Svecova, E. Anzenbacherova, R. Vrzal, F. Staud, Z. Dvorak, J. Ulrichova, P. Anzenbacher, and P. Pavek
Valproic Acid Induces CYP3A4 and MDR1 Gene Expression by Activation of Constitutive Androstane Receptor and Pregnane X Receptor Pathways
Drug Metab. Dispos., July 1, 2007; 35(7): 1032 - 1041.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
A. Takeshita, K. Inagaki, J. Igarashi-Migitaka, Y. Ozawa, and N. Koibuchi
The endocrine disrupting chemical, diethylhexyl phthalate, activates MDR1 gene expression in human colon cancer LS174T cells.
J. Endocrinol., September 1, 2006; 190(3): 897 - 902.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
T. Suzuki, Y. Miki, Y. Nakamura, T. Moriya, K. Ito, N. Ohuchi, and H. Sasano
Sex steroid-producing enzymes in human breast cancer
Endocr. Relat. Cancer, December 1, 2005; 12(4): 701 - 720.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2005 by The Endocrine Society